Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Amino Acids, Peptides, and Proteins (1)
- Biochemistry, Biophysics, and Structural Biology (1)
- Biological Phenomena, Cell Phenomena, and Immunity (1)
- Cancer Biology (1)
- Cellular and Molecular Physiology (1)
-
- Chemicals and Drugs (1)
- Endocrine System Diseases (1)
- Genetics and Genomics (1)
- Immunology and Infectious Disease (1)
- Immunopathology (1)
- Medicinal Chemistry and Pharmaceutics (1)
- Microbiology (1)
- Molecular Biology (1)
- Molecular Genetics (1)
- Neoplasms (1)
- Nutritional and Metabolic Diseases (1)
- Organismal Biological Physiology (1)
- Pharmacology, Toxicology and Environmental Health (1)
- Physiological Processes (1)
- Physiology (1)
Articles 1 - 2 of 2
Full-Text Articles in Medical Molecular Biology
Inhibition Of Ribosome Biogenesis Through Genetic And Chemical Approaches, Leonid Anikin
Inhibition Of Ribosome Biogenesis Through Genetic And Chemical Approaches, Leonid Anikin
Graduate School of Biomedical Sciences Theses and Dissertations
In order to maintain the ability to generate proteins, proliferating cells must continuously generate ribosomes, designating up to 80% of their energy to ribosome biogenesis (RBG). RBG involves transcription of rDNA by RNA polymerases I (Pol I) and III (Pol III), expression of approximately 80 ribosomal proteins, and assembly of these components in a process referred to as ribosome maturation. During maturation, the Pol I transcribed 47S pre-rRNA undergoes a number of processing events, while simultaneously interacting with processing factors and ribosomal proteins that drive pre-ribosome assembly. Inhibition of RBG has become one of the pursued targets for cancer therapy …
Loss Of Marv1 Promotes Chop Signaling In Mouse Liver, Shad Anthony Mitchell
Loss Of Marv1 Promotes Chop Signaling In Mouse Liver, Shad Anthony Mitchell
Graduate School of Biomedical Sciences Theses and Dissertations
Metabolic syndrome (MetS) is a term used to define a set of metabolic diseases: obesity, type 2 diabetes (T2D), hyperlipidemia, hypertension, nonalcoholic fatty liver disease (NAFLD), and nonalcoholic hepatosteatosis (NASH). Those with MetS have a higher incidence of cardiovascular disease and stroke. Current drug treatments for MetS treat the individual pathologies associated with the diseases, rather than directly targeting MetS as a whole. We hypothesize that the inhibition of a ubiquitous lipid transporter known as ARV1 can improve pathologies associated with MetS. To test this hypothesis, we utilized liver tissue from mARV1 knockout mice fed a high-fat diet and examined …